2 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMOCompleted
The primary objective of this study is to evaluate the efficacy of BIIB074 in treating pain experienced by subjects with confirmed SFN that is idiopathic or associated with diabetes mellitus.Sub study objective:Corneal Confocal Microscopy (CCM) as a…